Daré Launches First Consumer Health Product, Flora Sync LF5
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 25 2026
0mins
Source: Newsfilter
- First Consumer Health Product: Daré Bioscience announced the upcoming June 2026 launch of Flora Sync LF5™, a vaginal probiotic capsule designed to restore microbiome balance, marking the company's first foray into consumer health and expected to drive direct product revenue.
- Strategic Positioning: CEO Sabrina Martucci Johnson emphasized the significance of Flora Sync LF5™ within the company's diversified women's health strategy, aiming to address unmet needs through evidence-based solutions, thereby enhancing brand impact.
- Market Potential: The launch of Flora Sync LF5™ not only responds to the demand in the women's health market but also positions the DARE to RESTORE™ brand for future growth, further solidifying Daré's leadership in this sector.
- Scientific Foundation: The product's formulation is based on rigorous scientific research aimed at addressing critical issues in women's reproductive health, reflecting Daré's commitment to improving women's quality of life while laying the groundwork for future product development.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DARE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DARE
Wall Street analysts forecast DARE stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.080
Low
8.00
Averages
10.00
High
12.00
Current: 2.080
Low
8.00
Averages
10.00
High
12.00
About DARE
Dare Bioscience, Inc. is a biopharmaceutical company. The Company's programs target unmet needs in women's health, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. Its product includes XACIATO (clindamycin phosphate) vaginal gel 2%. XACIATO is a single-dose prescription medication for the treatment of bacterial vaginosis in females 12 years of age and older. Its other product candidates include Ovaprene, Sildenafil Cream, and DARE-HRT1. Ovaprene is an investigational, hormone-free, monthly intravaginal contraceptive. Sildenafil Cream is a novel cream formulation of sildenafil for the treatment of female sexual arousal disorder; and DARE-HRT1 is an intravaginal ring designed to deliver a combination of menopausal hormone therapy, bio-identical 17b-estradiol and progesterone together, continuously over a 28-day period for the treatment of moderate to severe vasomotor symptoms, also known as hot flashes.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Daré Launches First Consumer Health Product, Flora Sync LF5
- First Consumer Health Product: Daré Bioscience announced the upcoming June 2026 launch of Flora Sync LF5™, a vaginal probiotic capsule designed to restore microbiome balance, marking the company's first foray into consumer health and expected to drive direct product revenue.
- Strategic Positioning: CEO Sabrina Martucci Johnson emphasized the significance of Flora Sync LF5™ within the company's diversified women's health strategy, aiming to address unmet needs through evidence-based solutions, thereby enhancing brand impact.
- Market Potential: The launch of Flora Sync LF5™ not only responds to the demand in the women's health market but also positions the DARE to RESTORE™ brand for future growth, further solidifying Daré's leadership in this sector.
- Scientific Foundation: The product's formulation is based on rigorous scientific research aimed at addressing critical issues in women's reproductive health, reflecting Daré's commitment to improving women's quality of life while laying the groundwork for future product development.
See More
Daré Bioscience to Present at BIO International Convention 2026
- Women's Health Innovation: Daré Bioscience's CEO Sabrina Martucci Johnson will speak at the 2026 BIO International Convention, emphasizing innovation and solutions in women's health, showcasing the company's leadership in this underrepresented field.
- Industry Networking Platform: The convention will gather global biotech executives, investors, and policymakers, providing Daré with an exceptional opportunity to engage with potential partners and investors, further advancing innovation in women's health.
- Strategic Presentation: During the convention, Johnson will discuss Daré's corporate strategy and upcoming milestones, highlighting the company's commitment to addressing critical needs in women's health, thereby creating meaningful value for patients and shareholders.
- Clinical Development Challenges: Johnson will also participate in discussions on the challenges of clinical development for women's health products, exploring pathways to accelerate innovation and improve patient access, aiming to fill longstanding gaps in women's health research and development.
See More
Daré (DARE) Q4 2025 Earnings Call Transcript
See More
Daré Bioscience Initiates Phase 2 Clinical Trial for DARE-HPV
- Clinical Trial Launch: Daré Bioscience has announced the initiation of its Phase 2 clinical trial for DARE-HPV, aimed at evaluating a novel localized self-administered therapy for clearing high-risk HPV infections, potentially offering new treatment options for six million women annually.
- Funding Support: The project is backed by a $10 million contract from the U.S. government’s ARPA-H, with $9 million received to date, highlighting governmental commitment to innovation in women's health and potentially paving the way for further investments.
- Study Design: This trial is a randomized, double-blind, placebo-controlled study planned to involve approximately 100 women over a 21-day treatment period, primarily assessing HPV clearance rates at three months post-treatment, which could redefine current treatment paradigms if successful.
- Market Potential: If approved, DARE-HPV would be the first pharmacologic treatment for high-risk HPV infection, addressing a significant unmet need and potentially reducing cervical cancer incidence in the U.S., thus holding substantial public health significance.
See More
Daré Bioscience Q1 2026 Earnings Call Insights
- Financial Overview: Daré Bioscience ended Q1 2026 with approximately $18.5 million in cash and cash equivalents and $0.5 million in working capital, indicating tight financial management as the company faces upcoming product revenue and financing needs.
- Revenue Expectations: The company expects to begin recording product revenue from DARE to PLAY in Q3 2026, while Flora Sync LF5 is anticipated to generate revenue starting in June 2026, marking a significant commercial milestone as the first direct product revenue.
- Clinical Trial Progress: The Ovaprene clinical trial received a second consecutive recommendation to continue without modification, with approximately 9% of women experiencing pregnancy, providing positive support for future FDA approval and potentially enhancing the company's competitiveness in the consumer health product market.
- Financing Needs Warning: Management highlighted in the Q&A that “we will need to raise” capital, indicating that without expected revenue and grant disbursements, the current cash runway is insufficient for 12 months, underscoring potential liquidity risks for the company.
See More
Dare Bioscience Q1 Earnings Exceed Expectations
- Earnings Highlights: Dare Bioscience reported a Q1 GAAP EPS of -$0.20, beating expectations by $0.10, indicating potential improvements in the company's profitability outlook.
- Revenue Performance: The company generated $15.45M in revenue for Q1, a 39.2% year-over-year decline, yet it surpassed market expectations of $15.42M, demonstrating relative competitive strength amid challenges.
- Cash Position: As of March 31, 2026, Dare had approximately $18.5M in cash and cash equivalents, along with about $0.5M in working capital, reflecting solid financial management practices.
- Future Strategy: Dare Bioscience is implementing a multiplatform strategy aimed at launching new revenue streams in 2026, which is expected to enhance its market position and address current revenue challenges.
See More
Daré Launches First Consumer Health Product, Flora Sync LF5
- First Consumer Health Product: Daré Bioscience announced the upcoming June 2026 launch of Flora Sync LF5™, a vaginal probiotic capsule designed to restore microbiome balance, marking the company's first foray into consumer health and expected to drive direct product revenue.
- Strategic Positioning: CEO Sabrina Martucci Johnson emphasized the significance of Flora Sync LF5™ within the company's diversified women's health strategy, aiming to address unmet needs through evidence-based solutions, thereby enhancing brand impact.
- Market Potential: The launch of Flora Sync LF5™ not only responds to the demand in the women's health market but also positions the DARE to RESTORE™ brand for future growth, further solidifying Daré's leadership in this sector.
- Scientific Foundation: The product's formulation is based on rigorous scientific research aimed at addressing critical issues in women's reproductive health, reflecting Daré's commitment to improving women's quality of life while laying the groundwork for future product development.
See More
Daré Bioscience to Present at BIO International Convention 2026
- Women's Health Innovation: Daré Bioscience's CEO Sabrina Martucci Johnson will speak at the 2026 BIO International Convention, emphasizing innovation and solutions in women's health, showcasing the company's leadership in this underrepresented field.
- Industry Networking Platform: The convention will gather global biotech executives, investors, and policymakers, providing Daré with an exceptional opportunity to engage with potential partners and investors, further advancing innovation in women's health.
- Strategic Presentation: During the convention, Johnson will discuss Daré's corporate strategy and upcoming milestones, highlighting the company's commitment to addressing critical needs in women's health, thereby creating meaningful value for patients and shareholders.
- Clinical Development Challenges: Johnson will also participate in discussions on the challenges of clinical development for women's health products, exploring pathways to accelerate innovation and improve patient access, aiming to fill longstanding gaps in women's health research and development.
See More
Daré (DARE) Q4 2025 Earnings Call Transcript
See More
Daré Bioscience Initiates Phase 2 Clinical Trial for DARE-HPV
- Clinical Trial Launch: Daré Bioscience has announced the initiation of its Phase 2 clinical trial for DARE-HPV, aimed at evaluating a novel localized self-administered therapy for clearing high-risk HPV infections, potentially offering new treatment options for six million women annually.
- Funding Support: The project is backed by a $10 million contract from the U.S. government’s ARPA-H, with $9 million received to date, highlighting governmental commitment to innovation in women's health and potentially paving the way for further investments.
- Study Design: This trial is a randomized, double-blind, placebo-controlled study planned to involve approximately 100 women over a 21-day treatment period, primarily assessing HPV clearance rates at three months post-treatment, which could redefine current treatment paradigms if successful.
- Market Potential: If approved, DARE-HPV would be the first pharmacologic treatment for high-risk HPV infection, addressing a significant unmet need and potentially reducing cervical cancer incidence in the U.S., thus holding substantial public health significance.
See More
Daré Bioscience Q1 2026 Earnings Call Insights
- Financial Overview: Daré Bioscience ended Q1 2026 with approximately $18.5 million in cash and cash equivalents and $0.5 million in working capital, indicating tight financial management as the company faces upcoming product revenue and financing needs.
- Revenue Expectations: The company expects to begin recording product revenue from DARE to PLAY in Q3 2026, while Flora Sync LF5 is anticipated to generate revenue starting in June 2026, marking a significant commercial milestone as the first direct product revenue.
- Clinical Trial Progress: The Ovaprene clinical trial received a second consecutive recommendation to continue without modification, with approximately 9% of women experiencing pregnancy, providing positive support for future FDA approval and potentially enhancing the company's competitiveness in the consumer health product market.
- Financing Needs Warning: Management highlighted in the Q&A that “we will need to raise” capital, indicating that without expected revenue and grant disbursements, the current cash runway is insufficient for 12 months, underscoring potential liquidity risks for the company.
See More
Dare Bioscience Q1 Earnings Exceed Expectations
- Earnings Highlights: Dare Bioscience reported a Q1 GAAP EPS of -$0.20, beating expectations by $0.10, indicating potential improvements in the company's profitability outlook.
- Revenue Performance: The company generated $15.45M in revenue for Q1, a 39.2% year-over-year decline, yet it surpassed market expectations of $15.42M, demonstrating relative competitive strength amid challenges.
- Cash Position: As of March 31, 2026, Dare had approximately $18.5M in cash and cash equivalents, along with about $0.5M in working capital, reflecting solid financial management practices.
- Future Strategy: Dare Bioscience is implementing a multiplatform strategy aimed at launching new revenue streams in 2026, which is expected to enhance its market position and address current revenue challenges.
See More
